Lb Pharmaceuticals (LBRX) Invested Capital (2024 - 2026)

Lb Pharmaceuticals has reported Invested Capital for 3 years, with the latest figure at $379.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 482.37% year-over-year to $379.8 million; the trailing twelve-month figure through Mar 2026 stood at $379.8 million (up 482.37% YoY), and the FY2025 full-year result was $302.7 million, up 428.79% from the prior year.
• Invested Capital for Q1 2026 stood at $379.8 million, up from $302.7 million in the prior quarter.
• The five-year high for Invested Capital was $379.8 million in Q1 2026, with the low at -$99.3 million in Q1 2025.
• Average Invested Capital over 3 years is $118.5 million, with a median of $105.6 million recorded in 2024.
• Year-over-year, Invested Capital soared 428.79% in 2025 and soared 482.37% in 2026.
• Tracing LBRX's Invested Capital over 3 years: stood at -$92.0 million in 2024, then soared by 428.79% to $302.7 million in 2025, then grew by 25.5% to $379.8 million in 2026.
• The last three Invested Capital figures came in at $379.8 million (Q1 2026), $302.7 million (Q4 2025), and $311.2 million (Q3 2025), per Business Quant data.

Peer Comparison